ManagementManagementManagementManagement
  • OUR APPROACH
  • SCIENCE
  • PROGRAMS
  • TEAM
  • INVESTOR INFORMATION
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 22, 2022 8:30am EDT

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Mar 16, 2022 8:30am EDT

LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

Jan 12, 2022 8:30am EST

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Jan 05, 2022 8:30am EST

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Nov 22, 2021 9:25am EST

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

Oct 20, 2021 9:25am EDT

Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28

Oct 13, 2021 9:25am EDT

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Aug 17, 2021 9:25am EDT

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

Aug 03, 2021 9:25am EDT

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

Jul 22, 2021 9:25am EDT

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com

LIXTE Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About LIXTE
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2023 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. Site by Third Eye Industries
    Close